Open-laBel Dose-escalation Study for CRISPR/cas13- Rna TargetInG THerapy for the Treatment of Neovascular Age-related Macular Degeneration in Phase I Trial
Clinical trial NCT06623279 · NOT_YET_RECRUITING
Trial details
- NCT number
- NCT06623279
- Sponsor
- HuidaGene Therapeutics Co., Ltd.
- Status
- NOT_YET_RECRUITING
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2025-04-01
- Primary completion
- 2027-02-01
- Enrollment
- 15
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.